David Ramsay Takes the Helm as President of Drug Delivery at Halozyme Therapeutics

Halozyme Therapeutics Appoints David Ramsay as President of Drug Delivery

On June 30, 2026, Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced the appointment of David Ramsay as the President of Drug Delivery, in a move aimed at strengthening their innovative solutions in the biopharmaceutical sector. In this newly created position, Ramsay will oversee the comprehensive strategy and growth of the company’s drug delivery technologies, cementing his return to a leadership role after previously serving in various capacities within the organization.

Halozyme's CEO, Dr. Helen Torley, expressed her enthusiasm about Ramsay's appointment during a recent announcement, stating, "I am delighted to have a business leader of David's experience assume this new position at a time of unprecedented opportunity and growth for Halozyme." Torley noted that Ramsay’s extensive background will be instrumental in guiding Halozyme through a critical phase of expansion and further establishing the company’s financial and technological frameworks.

Ramsay, who has more than three decades of experience in strategic financial leadership across the biotechnology and life sciences sectors, previously held the role of Interim Chief Financial Officer at Halozyme. His prominent career includes significant contributions to capital markets, corporate finance, and operational growth, underscoring his capability to drive strategic initiatives at Halozyme.

In his most recent capacity, Ramsay successfully led financial operations for the company during a transitional period leading to the appointment of Darren Snellgrove as the new Chief Financial Officer. Notably, his earlier tenures at Halozyme, particularly as Chief Financial Officer, witnessed the firm’s growth from a private venture to a billion-dollar public biopharmaceutical powerhouse. Throughout those years, Ramsay played a pivotal role in building foundational systems for financial and technology commercialization.

With a fresh perspective as President of Drug Delivery, Ramsay shared his enthusiasm, stating, "I am thrilled to assume this new role at Halozyme at such an important time in the Company's evolution." He elaborated on the untapped potential of Halozyme’s diverse technology portfolio, emphasizing the company’s capabilities to significantly enhance biologic delivery. Collaborating with prominent biopharmaceutical partners could pave the way for lasting and new revenue streams, ultimately contributing to patient well-being and market growth.

Ramsay's educational background is equally impressive, holding a B.S. in business administration from the University of California, Berkeley, and an M.B.A. with dual concentrations in finance and strategic management from The Wharton School at the University of Pennsylvania.

Doctor Torley remarked that Ramsay’s strategic assessment skills and deep industry knowledge will contribute significantly to the value creation for shareholders. With the foundation set for robust collaboration and growth, Halozyme seems poised for an exciting future under Ramsay's leadership. The company is known for its ENHANZE® drug delivery technology, which has already improved the experiences and outcomes for over one million patients through ten commercial products worldwide.

The therapeutic possibilities continue to grow as Halozyme expands its drug delivery portfolio by incorporating innovative technologies like Hypercon™ and Surf Bio's advanced hyperconcentration technology. This expansion aims not only to enhance the standard of biologic delivery but also to make the administration process more efficient and accessible, catering to a wider array of patients.

Halozyme operates with a mission to develop and commercialize drug-device combinations that leverage advanced technologies, enhancing patient comfort and adherence. It is a pivotal time for the company, and with Ramsay’s strategic vision and leadership, Halozyme is set to navigate the intricacies of the evolving biopharmaceutical landscape successfully.

With headquarters based in San Diego, CA, alongside additional offices in New Jersey, Minnesota, and Massachusetts, Halozyme remains committed to advancing patient care through innovative solutions in drug delivery. As Ramsay embarks on this new role, the industry will be watching closely for how Halozyme’s pipeline evolves, ensuring better health outcomes for patients around the globe.